Treatment of hepatitis C in difficult-to-treat patients (Q38431523)

3 September 2017

1 reference

title

Treatment of hepatitis C in difficult-to-treat patients (English)

1 reference

3 September 2017

1 reference

Peter Ferenci

1

1 reference

PubMed ID

25895822

3 September 2017

language of work or name

English

0 references

publication date

21 April 2015

1 reference

Nature Reviews Gastroenterology & Hepatology

3 September 2017

1 reference

3 September 2017

12

1 reference

3 September 2017

284-292

1 reference

3 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2015.53

3 September 2017

0 references

cites work

Global control of hepatitis C: where challenge meets opportunity

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Hepatitis C and its impact on renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

An interferon-free antiviral regimen for HCV after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Impact of hepatitis B and C virus on kidney transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Boceprevir for untreated chronic HCV genotype 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

A glass half full: Implications of screening for hepatitis C virus in the era of highly effective antiviral therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Sticker shock and the price of new therapies for hepatitis C: is it worth it?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.53

A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluati

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25895822

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25895822

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2015.53

1 reference

3 September 2017

1 reference

PubMed ID

25895822